Cargando…

Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study

Male breast cancer (BC) represents less than 1% of male tumors. Little is known about male BC characteristics, management, and survival, with many studies based on a small number of cases. Consequently, the treatment of male BC lacks specific guidelines. The aims of the study are to compare male and...

Descripción completa

Detalles Bibliográficos
Autores principales: Accomasso, Francesca, Actis, Silvia, Minella, Carola, Rosso, Roberta, Granaglia, Claudia, Ponzone, Riccardo, Biglia, Nicoletta, Bounous, Valentina Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670254/
https://www.ncbi.nlm.nih.gov/pubmed/37999136
http://dx.doi.org/10.3390/curroncol30110716
_version_ 1785139880521629696
author Accomasso, Francesca
Actis, Silvia
Minella, Carola
Rosso, Roberta
Granaglia, Claudia
Ponzone, Riccardo
Biglia, Nicoletta
Bounous, Valentina Elisabetta
author_facet Accomasso, Francesca
Actis, Silvia
Minella, Carola
Rosso, Roberta
Granaglia, Claudia
Ponzone, Riccardo
Biglia, Nicoletta
Bounous, Valentina Elisabetta
author_sort Accomasso, Francesca
collection PubMed
description Male breast cancer (BC) represents less than 1% of male tumors. Little is known about male BC characteristics, management, and survival, with many studies based on a small number of cases. Consequently, the treatment of male BC lacks specific guidelines. The aims of the study are to compare male and female breast cancer (FBC) in terms of cancer clinical and anatomopathological features and treatment approach, and to identify differences between male BC and FBC in terms of survival. Patients and methods: Data from 2006 to 2018 were retrospectively acquired. Amounts of 49 males and 680 postmenopausal females with primary non-metastatic BC who underwent breast surgery at Mauriziano Hospital or IRCCS Candiolo (TO—Italy) were included. The mean age at diagnosis for male BC was 68.6 years, and males presented a smaller tumor size than women (p < 0.05) at diagnosis. Most male BC patients received adjuvant endocrine therapy (AET) with tamoxifen (73.5%). AET drop-out rate due to side effects was 16.3% for males compared to 7.6% for women (p = 0.04). Comparing FBC and male BC, no differences have been identified in terms of DFS and OS, with a similar 10-year-relapse rate (12% male BC vs. 12.4% FBC). Propensity Score Matching by age, nodal status, pT, and molecular subtype had been performed and no differences in OS and DFS were seen between male BC and FBC. In conclusion, male BC and FBC have similar prognostic factors and survival outcomes. The drop-out rate of AET was higher in males, and side effects were the main reason for drug discontinuation.
format Online
Article
Text
id pubmed-10670254
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106702542023-11-11 Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study Accomasso, Francesca Actis, Silvia Minella, Carola Rosso, Roberta Granaglia, Claudia Ponzone, Riccardo Biglia, Nicoletta Bounous, Valentina Elisabetta Curr Oncol Article Male breast cancer (BC) represents less than 1% of male tumors. Little is known about male BC characteristics, management, and survival, with many studies based on a small number of cases. Consequently, the treatment of male BC lacks specific guidelines. The aims of the study are to compare male and female breast cancer (FBC) in terms of cancer clinical and anatomopathological features and treatment approach, and to identify differences between male BC and FBC in terms of survival. Patients and methods: Data from 2006 to 2018 were retrospectively acquired. Amounts of 49 males and 680 postmenopausal females with primary non-metastatic BC who underwent breast surgery at Mauriziano Hospital or IRCCS Candiolo (TO—Italy) were included. The mean age at diagnosis for male BC was 68.6 years, and males presented a smaller tumor size than women (p < 0.05) at diagnosis. Most male BC patients received adjuvant endocrine therapy (AET) with tamoxifen (73.5%). AET drop-out rate due to side effects was 16.3% for males compared to 7.6% for women (p = 0.04). Comparing FBC and male BC, no differences have been identified in terms of DFS and OS, with a similar 10-year-relapse rate (12% male BC vs. 12.4% FBC). Propensity Score Matching by age, nodal status, pT, and molecular subtype had been performed and no differences in OS and DFS were seen between male BC and FBC. In conclusion, male BC and FBC have similar prognostic factors and survival outcomes. The drop-out rate of AET was higher in males, and side effects were the main reason for drug discontinuation. MDPI 2023-11-11 /pmc/articles/PMC10670254/ /pubmed/37999136 http://dx.doi.org/10.3390/curroncol30110716 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Accomasso, Francesca
Actis, Silvia
Minella, Carola
Rosso, Roberta
Granaglia, Claudia
Ponzone, Riccardo
Biglia, Nicoletta
Bounous, Valentina Elisabetta
Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
title Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
title_full Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
title_fullStr Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
title_full_unstemmed Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
title_short Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
title_sort clinical, pathological, and prognostic features of male breast cancer: a multicenter study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670254/
https://www.ncbi.nlm.nih.gov/pubmed/37999136
http://dx.doi.org/10.3390/curroncol30110716
work_keys_str_mv AT accomassofrancesca clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT actissilvia clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT minellacarola clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT rossoroberta clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT granagliaclaudia clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT ponzonericcardo clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT biglianicoletta clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy
AT bounousvalentinaelisabetta clinicalpathologicalandprognosticfeaturesofmalebreastcanceramulticenterstudy